sandoz pomalidomide capsule
sandoz canada incorporated - pomalidomide - capsule - 3mg - pomalidomide 3mg
sandoz pomalidomide capsule
sandoz canada incorporated - pomalidomide - capsule - 4mg - pomalidomide 4mg
pomalyst
celgene limited, a bristol myers squibb company - pomalidomide 1mg; - capsule - 1 mg - active: pomalidomide 1mg excipient: gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy
pomalyst
celgene limited, a bristol myers squibb company - pomalidomide 2mg; - capsule - 2 mg - active: pomalidomide 2mg excipient: erythrosine gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy
pomalyst
celgene limited, a bristol myers squibb company - pomalidomide 3mg; - capsule - 3 mg - active: pomalidomide 3mg excipient: gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy
pomalyst
celgene limited, a bristol myers squibb company - pomalidomide 4mg; - capsule - 4 mg - active: pomalidomide 4mg excipient: brilliant blue fcf gelatin indigo carmine mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy
pomalidomide sandoz
sandoz new zealand limited - pomalidomide 1mg - capsule - 1 mg - active: pomalidomide 1mg excipient: gelatin iron oxide red iron oxide yellow maltodextrin microcrystalline cellulose sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
pomalidomide sandoz
sandoz new zealand limited - pomalidomide 2mg - capsule - 2 mg - active: pomalidomide 2mg excipient: gelatin iron oxide red iron oxide yellow maltodextrin microcrystalline cellulose sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
pomalidomide sandoz
sandoz new zealand limited - pomalidomide 3mg - capsule - 3 mg - active: pomalidomide 3mg excipient: gelatin indigo carmine iron oxide red iron oxide yellow maltodextrin microcrystalline cellulose sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
pomalidomide sandoz
sandoz new zealand limited - pomalidomide 4mg - capsule - 4 mg - active: pomalidomide 4mg excipient: erythrosine gelatin indigo carmine iron oxide red iron oxide yellow maltodextrin microcrystalline cellulose sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.